Epsilogen Announces Acquisition of TigaTx, Inc. to Create World’s Leading Pan-Isotype Cancer Antibody Company
April 7, 2025
Highlights LONDON, UK and Boston, MA, 7 April 2025 – Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces